Cours RXi Pharmaceuticals Corp Nasdaq
Actions
US74979C8082
Recherche biotechnologique et médicale
CA 2024 * | - | CA 2025 * | - | Capitalisation | 3,18 M 2,89 M |
---|---|---|---|---|---|
Résultat net 2024 * | -13 M -11,81 M | Résultat net 2025 * | - | VE / CA 2024 * | - |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | - |
PER 2024 * |
-0,19
x | PER 2025 * |
-
| Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 99,41% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Varia. 1 janv. | Capi. | |
---|---|---|
+26,37% | 48,16 Md | |
-1,01% | 41,73 Md | |
+46,00% | 41,03 Md | |
-5,31% | 28,77 Md | |
+9,34% | 25,59 Md | |
-21,69% | 18,96 Md | |
+6,23% | 12,92 Md | |
+26,99% | 12,03 Md | |
-3,38% | 11,77 Md |